Smith & Nephew (S&N) is headquartered in London, UK, and is a global medical device company engaged in the development, manufacture and marketing of orthopaedic, endoscopy and advanced wound care products.
Prior to 2012, S&N was organised around three business units:
Orthopaedics – Focusing on orthopaedics reconstruction implants including hip, knee and shoulder joints, as well as ancillary products such as bone cement and mixing systems used in cemented reconstruction joint surgery; orthopaedic trauma fixation products consisting of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilisation of severe fractures and deformity correction procedures; and clinical therapies products such as bone growth stimulation, joint fluid therapies and out-patient pain management products. Included within the Orthopaedics segment was S&N’s biologics activities, which comprise research and development projects representing all three global business units.
Endoscopy – Focusing on the minimally-invasive sector of the endoscopy market through the provision of specialised devices and fixation systems to repair soft tissue and articulating joints.
Advanced Wound Management – Providing a range of products from initial wound bed preparation through to full wound closure.
During the second half of 2011, S&N implemented a re-organisation of its business as part of its new strategic plan for future growth. This plan includes the transfer of the majority of the company’s US Biologics team and Clinical Therapies business to a new joint venture – Bioventus LLC – with Essex Woodlands, a specialist healthcare growth equity and venture capital firm. It also includes simplifying and improving its operating model centred around two divisions – Advanced Surgical Devices (which combines the former Orthopaedics and Endoscopy segments) and Advanced Wound Management.
The S&N group is present in more than 90 countries and has a global workforce of more than 10,700 employees. In 2011, the company achieved net earnings of US$582 million on revenue of almost US$4.3 billion.
This company report provides
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)